WS #3939

The data dump reveals escalating geopolitical tensions with immediate market-moving potential. According to a Wall Street Journal report cited in multiple sources (314835203, 314835227, 314835148), US President Donald Trump is reportedly willing to end the Iran war even if the Strait of Hormuz remains largely closed, signaling a potential near-term de-escalation. This has triggered a sharp rally in US equity futures, with the Dow Jones up over 400 points (1.3%) as markets price in reduced conflict risk. However, this optimism is tempered by Trump's simultaneous aggressive rhetoric, including telling European allies to 'go get your own oil' from Hormuz (314835148, 314835227), highlighting ongoing friction and energy market stress. The conflict's impact is already material: US gasoline prices have surged above $4 per gallon, their highest since 2022 (314835150), and Lufthansa is considering flight cancellations in Europe due to soaring kerosene prices (314835237), directly affecting airlines and consumer spending. Concurrently, eurozone inflation surged to 2.5% in March, its highest in 14 months (314835135), driven by energy price spikes from the Iran conflict. This reinforces expectations for ECB rate hikes as early as April, corroborated by Bank of Italy Governor Panetta's warning of a 'vicious circle between prices and wages' (314835181). The inflationary shock is broad-based, with Brent crude futures up 5.25% to $118.7/barrel (314835203) and European natural gas prices rising. Corporate developments show mixed signals: NVIDIA's $2 billion investment in Marvell Technology (314835143, 314835172) is corroborated, likely boosting MRVL and signaling continued AI/chip sector momentum. In contrast, PepGen shares are trading lower after disappointing clinical data and a Wedbush price target cut (314835455), and Constellation Energy issued weak FY26 guidance despite a buyback increase (314835400). The FDA's adverse event monitoring system flagged potential new drug safety signals (314835510), which could pressure pharmaceutical stocks broadly if specific drugs are implicated.